DC Longitudinal Study on Aging and Specimen Bank
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age45+
SponsorGeorgetown University
About this trial
The Georgetown University Memory Disorders Program, part of the Department of Neurology, is conducting pilot studies of the feasibility of various diagnostic tests for Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. Further, this study is assessing longitudinal changes in biological, lifestyle, and cognitive assessment collection.
The primary goal of this study is to examine the feasibility of biochemical assays, genetic testing, and cognitive and lifestyle assessments in the ante-mortem diagnosis of Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. This research involves genetic and cognitive status testing but the findings will not be shared with research subjects. This will be accomplished ex vivo using blood, and/or cerebrospinal fluid (CSF) specimens from patients with a diagnosis of probable Alzheimer's disease, mild cognitive impairment, or other neurodegenerative diseases and from normal controls.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 45 and older.
Subjects within the age range of 45-50 years old must have a first degree relative with a neurodegenerative disease.
Disqualifiers
Individuals under 45 years of age
Trial population
All genders, races, and ethnicities eligible. Normal controls and those diagnosed with a neurodegenerative disorder eligible.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
1,000 Participants
are grouped into 2 trial groupsGroup A: Normal Cognition
Group B: Cognitive Disorder
Trial outcomes
Primary outcomes
1
CDR
Clinical Dementia Rating
Time frame
9 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov